Rentosertib UK

About this site

All sources

Every reference cited anywhere on the site, listed alphabetically with the pages that rely on it. 124 sources.

  1. Action for Pulmonary Fibrosis Used on: About idiopathic pulmonary fibrosis (IPF), Specialist ILD centres in the UK, IPF clinical trials recruiting in the UK, UK support, helplines and practical help
  2. Action for Pulmonary Fibrosis. State of the Nation survey, 11 March 2026 (1,270 respondents) Used on: About idiopathic pulmonary fibrosis (IPF)
  3. All Wales Therapeutics and Toxicology Centre (AWTTC) Used on: How a new medicine reaches NHS patients
  4. American Journal of Respiratory and Critical Care Medicine, ATS conference abstract: inhaled rentosertib pharmacokinetics Used on: Inhaled rentosertib
  5. American Journal of Respiratory and Critical Care Medicine, ATS conference abstract: inhaled rentosertib preclinical data Used on: Inhaled rentosertib
  6. Asthma + Lung UK helpline Used on: UK support, helplines and practical help
  7. Asthma + Lung UK. Pulmonary fibrosis information and helpline Used on: About idiopathic pulmonary fibrosis (IPF), IPF treatments available in the UK now
  8. Bender A, Thomas C, Scannell J et al. Nature Reviews Drug Discovery 2026 Used on: How AI was used to discover rentosertib
  9. Bowden A et al. UK consensus framework for familial pulmonary fibrosis. Thorax 2026 Used on: About idiopathic pulmonary fibrosis (IPF)
  10. Breathing Matters Used on: UK support, helplines and practical help
  11. British Thoracic Society UK ILD Registry, 2025 annual report (published June 2026) Used on: About idiopathic pulmonary fibrosis (IPF)
  12. British Thoracic Society. Pulmonary rehabilitation quality standard, 15 July 2026 Used on: IPF treatments available in the UK now
  13. British Thoracic Society. UK ILD Registry closure, June 2026, and BTS annual report 2025 Used on: Specialist ILD centres in the UK
  14. Buntz B. Insilico's AI-designed rentosertib in first Phase 2a results. Drug Discovery & Development, 5 June 2025 Used on: GENESIS-IPF: the Phase 2a trial in China
  15. Carers UK Used on: UK support, helplines and practical help
  16. Chemical & Engineering News coverage of the Nature Biotechnology paper, March 2024 Used on: How AI was used to discover rentosertib
  17. Chest Heart and Stroke Scotland Used on: UK support, helplines and practical help
  18. Civil Aviation Authority. Health and flying Used on: UK support, helplines and practical help
  19. ClinicalTrials.gov Used on: IPF clinical trials recruiting in the UK
  20. ClinicalTrials.gov NCT05154240 (Phase 1, New Zealand) Used on: Rentosertib clinical trials, Phase 0 and Phase 1: first studies in healthy volunteers, Safety and side effects seen so far
  21. ClinicalTrials.gov NCT05938920 (GENESIS-IPF, Phase 2a, China) Used on: What is rentosertib?, Rentosertib clinical trials, GENESIS-IPF: the Phase 2a trial in China, Frequently asked questions, Safety and side effects seen so far, Rentosertib and the UK
  22. ClinicalTrials.gov NCT05975983 (Phase 2a, United States) Used on: Rentosertib clinical trials, The US Phase 2a trial, Frequently asked questions
  23. ClinicalTrials.gov NCT07687459 (GENESIS-IPF-3, Phase III) Used on: What is rentosertib?, How AI was used to discover rentosertib
  24. ClinicalTrials.gov NCT07687459 (Phase 3, China) Used on: Rentosertib clinical trials, GENESIS-IPF-3: the Phase III trial, Frequently asked questions, Glossary, Rentosertib and the UK, Is rentosertib available in the UK?, IPF clinical trials recruiting in the UK
  25. Companies House search for Insilico entities (no UK company found, checked 14 September 2026) Used on: Insilico Medicine: the company behind rentosertib
  26. Corbyn Z. How AI uncovers new ways to tackle difficult diseases. BBC News, 10 January 2025 Used on: How AI was used to discover rentosertib
  27. Drug Discovery News: Qureight analyses of Insilico's Phase 2a rentosertib data, 15 July 2025 Used on: GENESIS-IPF: the Phase 2a trial in China, Rentosertib and the UK
  28. Drug Target Review: Insilico Medicine launches Phase III trial of AI-designed rentosertib Used on: GENESIS-IPF-3: the Phase III trial
  29. DrugBank record DB18083 Used on: What is rentosertib?
  30. DVLA. Respiratory and sleep disorders: assessing fitness to drive (26 September 2025) Used on: UK support, helplines and practical help
  31. EurekAlert: Insilico announces first dosing in China Phase 1 study, July 2022 (company press release) Used on: Phase 0 and Phase 1: first studies in healthy volunteers
  32. EurekAlert: positive topline results from the New Zealand Phase 1 study, January 2023 (company press release) Used on: Phase 0 and Phase 1: first studies in healthy volunteers
  33. European Lung Foundation. Airline oxygen index Used on: UK support, helplines and practical help
  34. European Respiratory Society Congress 2025 abstract OA1251 Used on: GENESIS-IPF: the Phase 2a trial in China
  35. Fahim A et al. Ten years of the British Thoracic Society UK ILD Registry (5,052 people with IPF, 2013 to 2023) Used on: About idiopathic pulmonary fibrosis (IPF)
  36. Genetic Engineering & Biotechnology News: Insilico eyes Q4 start for late-stage trials of IPF candidate, 3 June 2025 Used on: Rentosertib clinical trials, GENESIS-IPF-3: the Phase III trial, The US Phase 2a trial, Insilico Medicine: the company behind rentosertib
  37. Gonnelli F et al. Incidence and outcomes of interstitial lung disease in UK primary care (OPCRD). ERJ Open Research 2025 Used on: About idiopathic pulmonary fibrosis (IPF)
  38. GOV.UK. Apply for a Blue Badge Used on: UK support, helplines and practical help
  39. GOV.UK. Attendance Allowance Used on: UK support, helplines and practical help
  40. GOV.UK. Disabled Facilities Grants Used on: UK support, helplines and practical help
  41. GOV.UK. Get benefits if you're nearing the end of life Used on: UK support, helplines and practical help
  42. GOV.UK. Personal Independence Payment (PIP) Used on: UK support, helplines and practical help
  43. Gupta RS et al. Trends in the incidence and mortality of idiopathic pulmonary fibrosis in England. Thorax 2024;79:624 Used on: About idiopathic pulmonary fibrosis (IPF)
  44. Harvard Business School case: Insilico's Rentosertib Dilemma: A Star in the Pipeline? Used on: Insilico Medicine: the company behind rentosertib
  45. Health Research Authority. Recruitment guidance, section 6.2 Used on: IPF clinical trials recruiting in the UK
  46. HealthUnlocked. Asthma + Lung UK lung conditions community Used on: UK support, helplines and practical help
  47. Hospice UK hospice care finder Used on: UK support, helplines and practical help
  48. ILD Interdisciplinary Network. ILD-IN Service Evaluation, December 2023 (2022 data) Used on: Specialist ILD centres in the UK
  49. Insilico Medicine annual report 2025, filed with the Hong Kong Stock Exchange Used on: Insilico Medicine: the company behind rentosertib
  50. Insilico Medicine corporate site and pipeline (company material) Used on: Insilico Medicine: the company behind rentosertib
  51. Insilico Medicine doses first patient in GENESIS-IPF-3 (company press release) Used on: What is rentosertib?, How AI was used to discover rentosertib, Rentosertib clinical trials, GENESIS-IPF-3: the Phase III trial, Frequently asked questions, Insilico Medicine: the company behind rentosertib, Is rentosertib available in the UK?
  52. Insilico Medicine, 'Rentosertib and proteomic aging clocks' (company press release) Used on: The 'biological age' claims, explained
  53. Insilico Medicine: 2025 annual results, 29 March 2026 (company press release) Used on: Inhaled rentosertib, The US Phase 2a trial
  54. Insilico Medicine: first-in-human microdose study blog, November 2021 (company press release) Used on: Phase 0 and Phase 1: first studies in healthy volunteers
  55. Insilico Medicine: from target discovery to Phase 1 in 30 months (company page) Used on: How AI was used to discover rentosertib, Phase 0 and Phase 1: first studies in healthy volunteers
  56. Insilico Medicine: initiation of the Phase III trial, 7 July 2026 (company press release) Used on: GENESIS-IPF-3: the Phase III trial
  57. Insilico Medicine: Nature Medicine publication announcement, June 2025 (company press release) Used on: GENESIS-IPF: the Phase 2a trial in China
  58. Insilico Medicine: Phase 2a topline results, 12 November 2024 (company press release) Used on: GENESIS-IPF: the Phase 2a trial in China
  59. Insilico Medicine: rentosertib inhalation solution IND cleared in China (company press release) Used on: What is rentosertib?, Rentosertib clinical trials, Inhaled rentosertib
  60. International Business Times UK, 9 September 2026 Used on: The 'biological age' claims, explained
  61. ISRCTN registry Used on: IPF clinical trials recruiting in the UK
  62. Japan Times / Bloomberg coverage, 8 September 2026 Used on: The 'biological age' claims, explained
  63. Jayatunga MKP et al. BCG analysis of AI-derived molecules in clinical trials, Drug Discovery Today 2024 (PubMed 38692505) Used on: How AI was used to discover rentosertib
  64. King A. As AI-designed drug looks to pass final hurdle, will this tech change drug discovery forever? Chemistry World, 31 July 2025 Used on: How AI was used to discover rentosertib
  65. Longevity.Technology, 'Rentosertib puts aging clocks to the clinical test', 8 September 2026 Used on: The 'biological age' claims, explained
  66. Lowe D. So how is AI drug discovery doing, really? In the Pipeline, Science, 10 August 2026 Used on: How AI was used to discover rentosertib
  67. Marie Curie support line Used on: UK support, helplines and practical help
  68. Masuda M et al. TNIK inhibitor NCB-0846. Nature Communications 2016 Used on: How rentosertib is thought to work
  69. MedChemExpress product listing for a TNIK/MAP4K4 inhibitor (unverified secondary source) Used on: How rentosertib is thought to work
  70. Medicinal chemistry of the INS018_055 series. Journal of Medicinal Chemistry 2024 Used on: How rentosertib is thought to work
  71. MHRA launches AI sandbox to accelerate medicines development and improve safety, 9 June 2026 Used on: Rentosertib and the UK
  72. MHRA Yellow Card scheme Used on: Glossary, Safety and side effects seen so far
  73. MHRA, 'Nerandomilast (Jascayd) approved to treat adult patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis', 8 July 2026 Used on: Frequently asked questions, Rentosertib and the UK, How a new medicine reaches NHS patients, IPF treatments available in the UK now
  74. MHRA, ASA and GPhC joint warning on promoting unlicensed and newly licensed medicines, 18 June 2026 Used on: Frequently asked questions
  75. MHRA. Early Access to Medicines Scheme (EAMS) Used on: Is rentosertib available in the UK?, How a new medicine reaches NHS patients
  76. MHRA. Innovative Licensing and Access Pathway (ILAP) Used on: Is rentosertib available in the UK?, How a new medicine reaches NHS patients
  77. MHRA. International Recognition Procedure guidance (updated 3 September 2026) Used on: How a new medicine reaches NHS patients
  78. MHRA. Introducing new medicines: the UK pathway Used on: Is rentosertib available in the UK?, How a new medicine reaches NHS patients
  79. MHRA. Launch of clinical trial reforms, 28 April 2026 Used on: Rentosertib and the UK
  80. NHS Blood and Transplant. Lung transplantation Used on: Specialist ILD centres in the UK, IPF treatments available in the UK now
  81. NHS England. Service specification 17009/S, Interstitial lung disease (adults) Used on: How a new medicine reaches NHS patients, Specialist ILD centres in the UK
  82. NHS, idiopathic pulmonary fibrosis Used on: Glossary, About idiopathic pulmonary fibrosis (IPF), IPF treatments available in the UK now
  83. NHS. Help with prescription costs Used on: UK support, helplines and practical help
  84. NICE CG163. Idiopathic pulmonary fibrosis in adults: diagnosis and management (2013, updated 2017) Used on: About idiopathic pulmonary fibrosis (IPF), Specialist ILD centres in the UK, IPF treatments available in the UK now
  85. NICE guidance TA379 (nintedanib) and TA504 (pirfenidone) Used on: Glossary, IPF treatments available in the UK now
  86. NICE guidance TA379 (nintedanib), TA504 (pirfenidone), TA864 (nintedanib) and GID-TA11552 (nerandomilast, in development) Used on: Frequently asked questions, Rentosertib and the UK, How a new medicine reaches NHS patients, IPF treatments available in the UK now
  87. NICE QS79. Idiopathic pulmonary fibrosis in adults quality standard Used on: IPF treatments available in the UK now
  88. NICE TA379. Nintedanib for treating idiopathic pulmonary fibrosis (27 January 2016) Used on: IPF treatments available in the UK now
  89. NICE TA747. Nintedanib for treating progressive fibrosing interstitial lung diseases (November 2021) Used on: IPF treatments available in the UK now
  90. NICE TA864. Nintedanib for treating idiopathic pulmonary fibrosis with an FVC above 80% predicted (1 February 2023) Used on: IPF treatments available in the UK now
  91. NIHR Be Part of Research Used on: IPF clinical trials recruiting in the UK
  92. Northern Ireland Chest Heart and Stroke Used on: UK support, helplines and practical help
  93. Norwich Clinical Trials Unit. TIPAL trial (ISRCTN13526307) Used on: IPF clinical trials recruiting in the UK
  94. Office for National Statistics, deaths from idiopathic pulmonary fibrosis in England and Wales 2022 (freedom of information response FOI-2024-1766) Used on: About idiopathic pulmonary fibrosis (IPF)
  95. OneVoiceILD. Care Pathway report, April 2024 Used on: Specialist ILD centres in the UK
  96. Pharmaphorum. Insilico ends 2025 with US$293m Hong Kong IPO Used on: Insilico Medicine: the company behind rentosertib
  97. Phase 2a study protocol (ClinicalTrials.gov document) Used on: GENESIS-IPF: the Phase 2a trial in China
  98. Pliant Therapeutics investor relations: BEACON-IPF discontinuation of bexotegrast, June 2025 Used on: GENESIS-IPF-3: the Phase III trial
  99. PR Newswire: Insilico initiates Phase III clinical trial for rentosertib, 7 July 2026 (company press release) Used on: GENESIS-IPF-3: the Phase III trial
  100. Priority Services Register Used on: UK support, helplines and practical help
  101. PROFILE cohort survival analysis. BMJ Open Respiratory Research, January 2026 (PubMed 41605573) Used on: About idiopathic pulmonary fibrosis (IPF)
  102. PubChem compound record CID 164938183 Used on: What is rentosertib?
  103. Pulmonary Fibrosis NI Used on: UK support, helplines and practical help
  104. Pulmonary Fibrosis Trust Used on: UK support, helplines and practical help
  105. Qureight (Cambridge, UK) company information Used on: GENESIS-IPF: the Phase 2a trial in China
  106. RCSB Protein Data Bank entry 5D7A (TNIK kinase domain with NCB-0846) Used on: How rentosertib is thought to work
  107. Regalado A. An AI-driven 'factory of drugs' claims to have hit a big milestone. MIT Technology Review, 20 March 2024 Used on: How AI was used to discover rentosertib, Insilico Medicine: the company behind rentosertib
  108. Regalado A. When AI designs a drug, who gets the credit? MIT Technology Review, 21 August 2026 Used on: How AI was used to discover rentosertib, Insilico Medicine: the company behind rentosertib
  109. Ren F et al. 2024, open-access full text (PMC11738990) Used on: How AI was used to discover rentosertib, Phase 0 and Phase 1: first studies in healthy volunteers, How rentosertib is thought to work
  110. Ren F et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology 2024 Used on: What is rentosertib?, How AI was used to discover rentosertib, Rentosertib clinical trials, Inhaled rentosertib, Phase 0 and Phase 1: first studies in healthy volunteers, Glossary, How rentosertib is thought to work, Insilico Medicine: the company behind rentosertib, Safety and side effects seen so far
  111. Reuters. Eli Lilly signs deal worth up to about US$2.75bn with Insilico Medicine, 29 March 2026 Used on: Insilico Medicine: the company behind rentosertib
  112. Richeldi L et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine, 18 May 2025 Used on: How a new medicine reaches NHS patients, IPF treatments available in the UK now
  113. Scottish Medicines Consortium, medicines advice Used on: How a new medicine reaches NHS patients, IPF treatments available in the UK now
  114. Shen X. South China Morning Post, 19 December 2024 Used on: GENESIS-IPF: the Phase 2a trial in China
  115. Structural insight into TNIK inhibition (PMC9656744) Used on: How rentosertib is thought to work
  116. The New York Times, 'Early Data Indicates an A.I.-Generated Drug Could Slow Aging', 7 September 2026 Used on: The 'biological age' claims, explained
  117. TNIK as a therapeutic target: a review. Trends in Pharmacological Sciences 2024 Used on: How rentosertib is thought to work
  118. Toby M. Maher, Keck School of Medicine, University of Southern California Used on: The US Phase 2a trial
  119. USAN Council approves the name rentosertib, EurekAlert, March 2025 (company press release) Used on: What is rentosertib?
  120. Wikipedia: Rentosertib (chemical identifiers) Used on: What is rentosertib?
  121. Xu Z et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine 2025;31:2602–2610 Used on: What is rentosertib?, The 'biological age' claims, explained, How AI was used to discover rentosertib, Rentosertib clinical trials, GENESIS-IPF: the Phase 2a trial in China, GENESIS-IPF-3: the Phase III trial, Frequently asked questions, Glossary, How rentosertib is thought to work, Insilico Medicine: the company behind rentosertib, Safety and side effects seen so far, Rentosertib and the UK, Is rentosertib available in the UK?
  122. Xu Z et al., open-access full text (PMC12353801) Used on: GENESIS-IPF: the Phase 2a trial in China, Safety and side effects seen so far
  123. Zhavoronkov A et al. Nature Biotechnology, 7 September 2026 (proteomic ageing clocks analysis). DOI 10.1038/s41587-026-03286-y Used on: The 'biological age' claims, explained, Frequently asked questions
  124. Zitnik M. News and Views on the rentosertib phase 2a trial. Nature Medicine 2025 Used on: How AI was used to discover rentosertib, GENESIS-IPF: the Phase 2a trial in China